CDC on Monday issued a health alert saying providers should prioritize available doses of Beyfortus — a monoclonal antibody developed by Sanofi used to protect infants from respiratory syncytial virus (RSV) — for babies at highest risk of the disease in response to supply issues, in today's bite-sized hospital and health industry news from the District of Columbia, Georgia, and Pennsylvania.
Create your free account to access 1 resource, including the latest research and webinars.
You have 1 free members-only resource remaining this month.
1 free members-only resources remaining
1 free members-only resources remaining
You've reached your limit of free insights
Never miss out on the latest innovative health care content tailored to you.
You've reached your limit of free insights
Never miss out on the latest innovative health care content tailored to you.
This content is available through your Curated Research partnership with Advisory Board. Click on ‘view this resource’ to read the full piece
Email ask@advisory.com to learn more
Never miss out on the latest innovative health care content tailored to you.
This is for members only. Learn more.
Never miss out on the latest innovative health care content tailored to you.